Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects

Pharmacological Reviews

Volumn 53, Issue 1, 2001, Pages 119-133

  Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RACLOPRIDE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SPIPERONE; SULPIRIDE; THIORIDAZINE; VANOXERINE;

BRAIN CORTEX; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; ISOTOPE LABELING; LIGAND BINDING; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE;

EID: 0035101404     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Increased baseline occupancy of D-2 receptors by dopamine in schizophrenia
2. Do novel antipsychotics have similar pharmacological characteristics? A review of the literature
3. Neurotransmitter related genes and antipsychotic response: Pharmacogenetics meets psychiatric treatment
4. Pharmacogenetic prediction of clozapine response
5. 4 receptor repeat: Analysis of different native and mutant forms of the human and rat genes
6. Tissue concentrations of clozapine and its metabolites in the rat
7. 123I]epidepride single photon emission tomography (SPET) study
8. 3 receptors by typical antipsychotic drugs
9. Operational models of pharmacological agonism
10. Schizophrenia is associated with elevated amphetamine induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
11. 4 receptor antagonist
12. Anomalous equilibrium binding properties of high affinity radioligands
13. Quantitative aspects of hormone receptor interaction of high affinity. Effect of receptor concentration and measurement of affinity constants of labelled and unlabelled hormones
14. 1B receptor-reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties
15. 4.4receptors expressed in CHO cells
16. 2 dopamine receptor missense variants
17. 2 dopamine missense variants
18. Dopamine receptors and average clinical doses
19. Dopamine receptor occupancy and plasma haloperidol levels
20. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine
21. 2 dopamine receptors in healthy subjects and antipsychotic drug treated patients
22. Neuroleptics increase c-fos expression in the forebrain - Contrasting effects of haloperidol and clozapine
23. In vivo imaging of neuromodulatory synaptic transmission using PET: A review of relevant neurophysiology
24. 2(short) dopamine receptors determined in ligand binding and functional assays
25. Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex and striatum, an in vivo voltammetry study
26. Atypical antipsychotics: An inspiring but confusing concept
27. 2 dopamine receptors in monkey brain
28. The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors
29. Dopamine cell depolarisation block as a model for the therapeutic actions of antipsychotic drugs
30. 3 receptor ligand (+)-UH 232 is a partial agonist
31. 3 dopamine receptor
32. 2 receptor occupancy by an atypical neuroleptic
33. 2 dopamine receptors
34. 2 dopamine receptors by amiloride and amiloride analogues
35. Strategy and tactics in receptor binding studies
36. 2 receptors: Distribution, pharmacological characterisation and regionally specific regulation by clozapine
37. Profound neuronal plasticity in response to inactivation of the dopamine transporter
38. 2 receptors in basal ganglia and cortex of human brain
39. What makes an antipsychotic atypical? Should the definition be preserved
40. 2 receptors explains atypical antipsychotic action - A new hypothesis
41. 2 occupancy, clinical response and side effects - A double blind PET study in first episode schizophrenia
42. 2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia
43. 2 dopamine receptor binding differences of clozapine and haloperidol
44. Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum
45. 4 dopamine receptor variants with Giα subtypes
46. Evidence for striatal dopamine release during a video game
47. 1 dopamine receptor
48. Effects of the D-3 and autoreceptor preferring dopamine antagonist (+)-UH 232 in schizophrenia
49. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review
50. Dopamine as the wind of the psychotic fire, new evidence from brain imaging studies
51. Increased dopamine transmission in schizophrenia: Relationship to illness phases
52. 2 receptor occupancy by endogenous dopamine in humans
53. Microdialysis and SPECT measurements of amphetamine induced dopamine release in nonhuman primates
54. The cerebral cortex: A case for a common site of action of antipsychotics
55. 3 receptors
56. 2 receptors: Evidence for identical binding sites
57. 35S] binding
58. Optimal dose of neuroleptic for schizophrenia: A controlled study of neuroleptic threshold and higher haloperidol dose
59. Cognition, schizophrenia and the atypical antipsychotic drugs
60. The regulation of forebrain dopamine transmission: Relevance to the pathophysiology and psychopathology of schizophrenia
61. The kinetics of competitive radioligand binding predicted by the law of mass action
62. The dopamine receptors
63. 2 receptors
64. Non-equipotent doses partly explain differences among antipsychotics - Implications of PET studies
65. 2 receptor occupancy during low dose treatment with haloperidol decanoate
66. 2 receptor occupancy in relation to clozapine serum concentration. A PET study of schizophrenic patients
67. 2 dopamine receptor occupancy in relation to antipsychotic effect: A double blind PET study of schizophrenic patients
68. 4 receptor
69. Dopamine release from nigral transplants visualised in vivo in a Parkinson's disease patient
70. 2 dopamine receptor occupancy in clozapine treated patients
71. Limbic selectivity of clozapine
72. Atypical antipsychotics: Are some more atypical than others
73. Induction patterns of fos like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity
74. Pharmacogenetics and future drug development and delivery
75. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
76. Imaging of neurotransmitter receptors in the living human brain
77. 4 receptors
78. Antipsychotic drug doses and neuroleptic/dopamine receptors
79. 2 receptors, yet occupy higher levels of these receptors
80. 2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
81. 3H]spiperone depend on tissue concentration: Analysis and examples
82. Dopamine receptor pharmacology
83. 4 receptor varies with the affinity of the competing ligand
84. 4 receptor subtypes and response to clozapine
85. An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis
86. Dopamine receptor binding on intact cells
87. The dopamine receptors
88. 123I]epidepride single photon emission tomography (SPET) scanning study
89. Commentary on atypical neuroleptics
90. 11C]raclopride? PET studies combined with microdialysis in conscious monkeys
91. Drug distribution between blood and brain as a determinant of antipsychotic drug efficacy
92. 4 dopamine receptor with high affinity for the antipsychotic clozapine
93. 4 receptor variants in the human population
94. What makes an antipsychotic atypical? Conserving the definition
95. Competitive binding studies with multiple sites. Effects arising from depletion of the free ligand
96. 3 agonist PD 128907 on brain dopamine synthesis in the rat
97. 2 dopamine receptor that adopts the activated conformation
98. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with caudate nucleus
99. 2 dopamine receptors in the basal ganglia of the rat -Light and electron microscopy